http://www.engeneinc.com () —

enGene Inc., a privately held biotechnology company developing an
innovative platform technology to deliver nucleotides (DNA or siRNA)
to mucosal tissue for treating a variety of diseases, including
inflammatory bowel disease (IBD) and diabetes, announced today that
Dr. Russell J. Mumper has joined the Company's Scientific Advisory
Board.

Dr. Mumper is an internationally recognized leader in developing
nanotechnologies for drug delivery. He is currently the Executive
Associate Dean for Academics and the John A. McNeill Distinguished
Professor at the UNC Eshelman School of Pharmacy at the University of
North Carolina (UNC) at Chapel Hill. He also serves as the Director of
the Center for Nanotechnology in Drug Delivery at UNC. Dr. Mumper has
contributed extensively to the fields of nano-scale drug delivery
systems, drug-polymer conjugates, and trans-mucosal drug and vaccine
delivery. He has received over $14 million in research grants and
contracts, authored more than 215 scientific publications/abstracts
and holds 38 granted and pending patents. Notably, Dr. Mumper was the
first scientist to demonstrate the use of chitosan as a carrier for
nucleotides and holds the earliest patent in this field.

"I'm impressed by the in vivo efficacy of the nucleotide delivery
system developed by enGene's scientists and the potential of the
technology to address critical unmet needs in medicine," says Dr.
Mumper.

"We are very pleased to have Dr. Mumper join our Scientific Advisory
Board. He brings to enGene a wealth of knowledge and expertise in
formulation of nanoparticles for pharmaceutical applications, drug
development and large-scale cGMP manufacturing of nanoparticles," says
Anthony T. Cheung, enGene's Chief Scientific Officer. "Dr. Mumper's
in-depth expertise in trans-mucosal drug delivery and formulation and
engineering of nanoparticles will be extremely relevant to enGene's
current research direction, as we embark on developing an oral
formulation for our nucleotide delivery system. We look forward to his
strategic contribution to our research and development programs."

More about enGene

enGene Inc. has developed a highly flexible, biopolymer-based
nucleotide (DNA and siRNA) delivery technology targeting mucosal
tissues to treat numerous prevalent, chronic diseases via the
induction or suppression of protein expression levels. Our platform
technology has the ability to significantly impact diseases of mucosal
tissues such as the gastrointestinal tract, lung and bladder as well
as provide systemic release of proteins from the gut to treat
diabetes, anemia, hemophilia and others. The two lead programs are the
localized delivery of an anti-inflammatory cytokine, IL-10, for
treating Inflammatory Bowel Disease and delivery of insulin in a
physiologic, meal-dependent fashion to regulate blood glucose levels.
For more information please visit www.engeneinc.com
(http://www.engeneinc.com) .